ReviewRadiologie (Heidelberg, Germany)2026
[Overview of CAR-T cell therapy : What the radiologist should know].
Review in Radiologie (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
clinical issueCAR-T cell therapy is complex and is now offered at a growing number of oncology centers in Germany. In addition to the initial CAR-T cell treatment, several advances and complementary therapies are available, which radiologists should be familiar with to properly evaluate treatment response and detect side effects early. STANDARD TREATMENT: In hemato-oncologic diseases, combinations of chemotherapy and targeted therapies are usually administered. TREATMENT INNOVATIONS: CAR-T-cell therapy combined with complementary immunotherapies. DIAGNOSTIC WORK-UP: For current indications, cross-sectional imaging-typically positron emission tomography/computed tomography-is used for staging and for evaluating therapy response. PERFORMANCE: The response rate is approximately 66.4% (25.5-90.9%). ACHIEVEMENTS: CAR-T cell therapy represents a new era in immunotherapy, and its recent advances mark a significant innovation in oncologic treatment. PRACTICAL RECOMMENDATIONS: Radiologists should understand the principles of CAR-T cell therapy in order to accurately assess treatment response and recognize early signs of potential side effects.
Indexed as
Identifiers
41361665What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.